We investigated the in-vitro antiproliferative effects and mechanism of action of both enantiomers of the bis-triazole derivative ICI 195,739 against epimastigotes and amastigotes of Trypanosoma cruzi, the aetiological agent of Chagas' disease. It has recently been shown that the R(+) enantiomer, D0870, can induce radical parasitological cure in murine models of the acute and chronic forms of the disease. D0870 dose-dependently affected the growth rate of the epimastigote form (IC 50 = 0.1 M; MIC = 1-3 M). The S(-) enantiomer was much less active (IC 50 = 3 M). Growth arrest and cell lysis induced by D0870 coincided with the complete depletion of endogenous 4,14-desmethyl sterols and their replacement by 4,14trimethyl and dimethyl sterols. The S(-) enantiomer produced qualitatively similar changes but to a lesser extent. D0870 inhibited the incorporation of radioactivity from [2-14 C]acetate into the epimastigote's 4,14-desmethyl sterols with an IC 50 of 50 nM while the corresponding concentration for the S(-) enantiomer was 3 M. D0870 eradicated the intracellular (amastigote) form of the parasite from cultured Vero cells at 10 nM; a 100-fold higher concentration of the S(-) enantiomer was required to produce a similar effect, and deleterious effects of the host cells were observed at >100 nM. At the MIC of D0870 the endogenous amastigote sterols (ergosta-7-en-3 -ol, 24-ethyl-cholesta-7-en-3 -ol and ergosta-7, 24(24 1 ) dien-3 -ol) were also largely replaced by lanosterol and 24-methyl-dihydrolanosterol. Combinations of D0870 and inhibitors of sterol 24(25) sterol methyltransferase (such as 22,26azasterol and 24(R,S),25-epiminolanosterol) acted synergically against the intracellular forms. Taken together these results indicate that, although both enantiomers have anti-T. cruzi activity, the specific activity of the R(+) enantiomer (D0870) is nearly two orders of m a gnitude higher than that of its S(-) analogue. However, as the in-vitro activity of D0870 is comparable to that of standard azoles, such as ketoconazole, its remarkable in-vivo antiparasitic activity may only be explained by its particular pharmacokinetic properties.
Introduction
Parasitological cure of American trypanosomiasis or Chagas' disease has remained an elusive goal, despite recent advances in understanding of the biochemistry and physiology of its aetiological agent, Trypanosoma (Schizotrypanum) cruzi. [1] [2] [3] [4] Currently used drugs such as nitrofurans and nitroimidazoles act by producing oxidative stress or reductive damage. They have been used with varying degree of success in acute cases but have no activity in the more prevalent chronic condition. Moreover, both drugs have serious side effects, including anorexia, vomiting, peripheral polyneuropathy and allergic dermopathy. 2 Sterol biosynthesis inhibitors (SBIs) are currently the most commonly used antifungal chemotherapeutic agents, whose effects are based on the specific depletion of endogenous fungal sterols and/or the accumulation of toxic biosynthetic intermediates. [5] [6] [7] Although T. cruzi also has an essential requirement for endogenous sterols throughout its life cycle, [8] [9] [10] [11] [12] clinically used SBIs cannot induce parasitological cure in human or animal model infections. [13] [14] [15] Figure 1 ) is a bis-triazole derivative 16 and was shown by Ryley et al. 17 to have a broad spectrum of activity against experimental systemic fungal infections, and specific anti-T. cruzi activity in a murine model. Work in our laboratory confirmed this activity, both in vitro and in vivo, and provided evidence for a dual mechanism of action of this compound against the parasite, which involves simultaneous blockade of the endogenous sterol biosynthetic pathway and cytokinesis. [18] [19] [20] More recent work has shown that the specific antifungal activity resides in the R( ) enantiomer, code-named D0870, [21] [22] [23] [24] [25] [26] [27] and we have recently shown that this compound can induce radical parasitological cure of murine models of both acute and chronic experimental Chagas' disease. 28 In this report we present the results of detailed in-vitro and biochemical studies of both enantiomers of ICI 195,739 against this parasite.
Materials and methods

Organisms
The EP stock of T. cruzi 29 was used throughout this work. Live T. cruzi were handled according to established guidelines. 30 Drugs D0870 and its S( ) enantiomer were provided by Zeneca Pharmaceuticals, Macclesfield, UK through Dr John F. Ryley. 22, 32 was synthesized and characterized as described elsewhere. 11 24,25-(R,S)-Epiminolanosterol was synthesized according to Parish & Nes 33 and characterized by gas-liquid chromatography/mass spectroscopy, 1 H-and 13 C-NMR and FT-IR spectroscopy. These drugs were added as dimethylsulphoxide (DMSO) solutions; the final DMSO concentration in the culture media never exceeded 1% (v/v) and had no effect by itself on the proliferation of the parasites or Vero cells.
In-vitro studies
The epimastigote form of the parasite was cultivated in liver infusion tryptose (LIT) 29 medium supplemented with 10% newborn calf serum (Gibco) at 28°C with rapid agitation (120 rpm); the cultures were initiated at a cell density of 2 10 6 epimastigotes/mL and the drugs were added at a cell density of 1 10 7 epimastigotes/mL. Cell densities were measured with an electronic particle counter (model ZBI; Coulter Electronics Inc., Hielah, FL, USA) and by direct counting with a haemocytometer. Cell viability was followed by Trypan Blue exclusion using light microscopy. Amastigotes were cultured in Vero cells maintained in minimal essential medium (MEM) supplemented with 1% fetal calf serum in a humidified 95% air-5% CO 2 atmosphere at 37°C as previously described. 10, 18, 34 Large-scale production of amastigotes required for biochemical studies was carried out as follows: Vero cells were superinfected at a ratio of 200 trypomastigotes/cell for 2 h and then washed three times with PBS to remove non-adherent parasites; medium was added and the cells were incubated for 48 h; fresh medium with or without drugs was then added and incubation continued for another 48 h. Heavily infected cells were removed from culture flasks by controlled trypsinization and washed three times by centrifugation (1000g for 10 min); the washed cells were suspended in MEM with a cocktail of protease inhibitors (5 mM iodoacetamide, 2 mM phenylmethylsulphonylfluoride, 10 mg/mL N-tosyl-L-phenylalanine-chloromethylketone, 2800 IU of aprotinin) and disrupted in a Parr pump using a pressure of 250 psi. The amastigotes were collected by centrifugation at 3000g for 15 min, resuspended in MEM containing protease inhibitors and layered on top of a 25% metrizamide solution in MEM. The discontinuous density gradient was centrifuged at 18,000g for 30 min and purified amastigotes ( 99% pure as judged by optical microscopy with no intact host cells in the preparation) were obtained at the interface and washed three times as indicated above. The washed amastigote pellet was used for lipid extraction as described below.
Studies of lipid composition and biosynthesis
To analyse the effects of drugs on the sterol composition of the epimastigotes and amastigotes, total lipids from control and drug-treated cells were extracted and fractionated by silicic acid column chromatography as described before. 10, 11 Preliminary analysis of the neutral lipid fractions was by thin layer chromatography (on Merck 5721 silica gel plates with heptane:isopropyl ether:glacial acetic acid (60:40:4) as developing solvent) and conventional gas-liquid chromatography (isothermic separation in a 4 m glass column packed with 3% OV-1 on Chromosorb 100/200 mesh, with nitrogen as carrier gas at 24 mL/min and flame ionization detection in a Varian 3700 gas chromatograph). For quantitative analysis and structural assignments the neutral lipids were separated in a capillary high resolution column (25 m 0.20 mm id Ultra-2 column, 5% phenylmethylsiloxane, 0.33 m film thickness) in a Hewlett-Packard 5890 series II gas chromatograph equipped with a HP5971A mass sensitive detector. The lipids were injected in ethyl acetate and the column was kept at 50ºC for 1 min, then the temperature was increased to 270ºC at a rate of 25ºC/min and finally to 300ºC at a rate of 1ºC/min. The flow of carrier gas (helium) was kept constant at 1.0 mL/min. The injector temperature was 250ºC and the detector was kept at 280ºC.
To study the de-novo synthesis of lipids, 0.025 Ci of [2-14 C]acetate (New England Nuclear, 55 mCi/mmol) was added to the cultures 24 h after the addition of the drug or carrier to the cultures and incubation was continued for a further 48 h. The lipids were then extracted, purified and analysed as described above. 9, 10, 18 The radioactive fractions from the thin layer chromatography were detected by autoradiography with Kodak XRP-5 plates, scrapped off and counted by liquid scintillation spectrometry in an LKB Rack-Beta counter, working at 80% efficiency for 14 C.
Results
Effects on epimastigotes
The antiproliferative effects of D0870 and its S(-) enantiomer on the epimastigote form of T. cruzi grown in LIT medium at 28°C are shown in Table I shows that in epimastigotes incubated for 120 h with the MIC of D0870 (3 M), 98% of the endogenous 4,14desmethyl sterols (ergosterol, 24-ethyl-cholesta-5,7,22trien-3 -ol and precursors) were replaced by 4,14dimethyl and trimethyl sterols, such as lanosterol, 24methylene-dihydrolanosterol and 4,14-dimethyl-ergosta-8,24(24 1 )-3 -ol (obtusifoliol). This confirmed that a primary target of the drug was the parasite's sterol 14 - demethylase. However at the IC 50 (0.1 M) only 20% of the endogenous sterols were 4,14-dimethyl or trimethyl sterols. The S(-) enantiomer was also much less effective as a modifier of the epimastigote's sterol composition: after a 120 h incubation with 3 M of this compound, about 30% of the endogenous sterols were still 4,14desmethyl sterols. As may be seen in Figure 3 , D0870 was very effective in blocking [2-14 C]acetate incorporation into the parasite's 4,14-desmethyl sterols with an IC 50 of 50 nM (Figure 3a) , while the corresponding concentration for the S( ) enantiomer was 3 M (Figure 3b ).
Effects on amastigotes
D0870 completely eradicated the intracellular amastigote form of the parasite from cultured Vero cells 10, 12, 18, 34 at 10 nM (Figure 4a ) while a 100-fold higher concentration was required for the S(-) enantiomer (Figure 4b ). D0870 did not signficantly affect the number or morphology of the host cells up to the maximum concentration tested (1 M), but for the S(-) enantiomer the number of cells declined steadily as a function of the drug concentration. There were also gross morphological alterations, including rounding, vacuolization and detachment, at 100 nM of this compound. We also analysed the sterol content of the amastigotes, isolated and purified from the host cells as described in Materials and methods. The results (Table II) The table shows the mass percent distribution of free sterols present in exponential phase epimastigotes grown in the absence or presence of the indicated concentrations of drugs. These cells also contained exogenously-derived cholesterol at levels approximately 20% of the total free sterol mass. Antiproliferative effects of D0870 on T. cruzi revealed that following 48 h incubation at the MIC of D0870, the normal endogenous amastigote sterols (ergosta-7-en-3 -ol; ergosta-7,24(24 1 )-dien-3 -ol and 24ethyl-cholesta-7-en-3 -ol) were largely replaced by lanosterol and 24-methyl-dihydrolanosterol. This indicated that against this form of the parasite the antiproliferative effects of the drug were also associated with the depletion of the parasite's specific sterols. Additional support for this hypothesis was suggested by the observation that combinations of D0870 with inhibitors of sterol 24(25) methyltransferase (24(25)-SMT) 11, 12, 31, 32, [35] [36] [37] acted synergically against the amastigotes. It can be seen from Figure 5 that the presence of only 10 nM of 22,26-azasterol or 24(R,S),25-epiminolanosterol, which by themselves have no significant effect on the intracellular parasite proliferation, reduced the MIC of D0870 to 1 and 3 nM, respectively. Synergic effects in the combined action of the drugs are expected for compounds that interfere with sequential steps of the same metabolic pathway. 10, 12, 34, 38 The amastigotes also con-tained high levels of cholesterol, probably derived from the host cells, which could fulfil basic structural membrane functions while the specific parasite sterols could be associated with essential 'metabolic' functions, as found previously in fungi and yeasts. [39] [40] [41] 
Discussion
The 'delayed lytic effect' of D0870 on T. cruzi epimastigotes (Figure 2a ), in which complete growth arrest and cell lysis take place only after the preformed 4,14desmethyl sterols are depleted (Table I) , is a characteristic phenomenon observed with all other SBIs studied with this organism. [9] [10] [11] [12] 18, 34, 38 However, the dose-dependent effect of the bis-triazole on the growth rate is at variance with the situation observed with other C1 -demethylase inhibitors, where no significant effect on this parameter was observed and growth arrest occurred suddenly at the sterol depletion point. 9, 10, 18, 34 Nevertheless, a similar effect on the growth rate was previously observed with the racemic compound ICI 195,739 18 and we presented evidence indicating that it could be associated with a direct interference of the compound on cytokinesis, separate from its inhibitory action on the parasite's de-novo sterol synthesis. 18, 19 On the other hand, the significantly lower effect of the S(-) enantiomer on parasite proliferation (Figure 2b ) correlated well with its weaker inhibitory action on de-novo sterol synthesis (Figure 3 ) as the ratios of the IC 50 s for the two effects were close (30 and 60, respectively). Moreover, the lack of complete growth arrest with the S(-) enantiomer in the concentration range tested (up to 3 M) was consistent with its inability to deplete the endogenous 4,14-desmethyl sterols (Table I) . All these facts support the notion that the primary mechanism of action of both compounds on the epi-mastigotes is interference with the parasite's sterol biosynthesis.
The activity of both D0870 and its S( ) enantiomer against the clinically relevant intracellular amastigote form (Figures 4 and 5 ) was, as with other SBIs, 10, 12, 18, 34 two orders of magnitude higher than against the epimastigotes, but, again, the R( ) enantiomer was 100 times more potent (Figure 3) . Moreover, the deleterious effects of the S( ) enantiomer on the host cells at 100 nM indicated that its therapeutic index was at least 1000-fold lower than that of D0870. The depletion of specific sterols of the amastigotes (Table II) by D0870 and the potentiation of its activity by other SBIs acting at a different point in the pathway strongly support the hypothesis that its primary mechanism of action is associated with the blockade of the parasite's sterol synthesis, as against the epimastigotes. 
Antiproliferative effects of D0870 on T. cruzi
Recent work in our group has shown that D0870 has a remarkable in-vivo activity in murine models of both acute and chronic Chagas' disease, being 30-fold more potent that ketoconazole, and is capable of producing radical parasitological cure of the infection. 28, 42 However, the invitro effects of D0870 on the proliferation and sterol biosynthesis of T. cruzi epimastigotes and amastigotes observed in this study were comparable to those previously obtained with ketoconazole [8] [9] [10] [11] [12] 34, 43 and thus cannot explain the higher in-vivo activity of the triazole. Recent work 44 analysed the molecular basis for the higher activity of D0870 against clinical isolates of Candida albicans in comparison with fluconazole and concluded that it must be related to differences in uptake or efflux of the drugs, as the intrinsic sensitivities of the cell-free sterol C14 -demethylation systems of the isolates to the drugs were comparable. In our case, studies were made with whole cells, including intracellular amastigotes, and the very similar results obtained with D0870 and ketoconazole indicate that the intrinsic sensitivity of the target enzyme combined with steady state intracellular drug levels led to the same degree of inhibition of the parasite's sterol biosynthesis pathway for both drugs, which correlated with the antiproliferative effects. Thus, the higher antiparasitic activity in vivo of D0870 when compared with ketoconazole and related compounds is most probably explained by the special pharmacokinetic properties of the former. In particular, the much longer plasma half-life in both humans and rodents, 22, 45, 46 should maintain high intracellular levels in the host's tissues.
In conclusion, our in-vitro studies indicate that, although both enantiomers of ICI 195,739 have anti-T. cruzi activity, the specific activity associated with the blockade of the parasite's sterol biosynthesis can be accounted for primarily by the R( ) enantiomer, D0870. However, as the in-vitro activity of this compound is comparable to that of standard azoles, its remarkable invivo antiparasitic activity may only be explained by its particular pharmacokinetic properties. 
